RPL36P13: A Promising Drug Target / Biomarker (G100271013)

Target Name: RPL36P13

NCBI ID: G100271013

RPL36P13

Other Name(s): RPL36_5_837 | ribosomal protein L36 pseudogene 13 | Ribosomal protein L36 pseudogene 13

RPL36P13: A Promising Drug Target / Biomarker

The protein RPL36P13 is a key regulator of the Replication Protein complex (RPC) in eukaryotic cells. The RPC is responsible for ensuring the accurate and orderly replication of DNA in the cell. Replication is a critical process for cell growth, development, and survival, and errors in replication can lead to various diseases, including cancer. Therefore, the regulation of the RPC by RPL36P13 is of great interest and potential as a drug target or biomarker.

Structure and Function

RPL36P13 is a 21-kDa protein that contains 116 amino acid residues. It is a member of the P11 subfamily of the Rpl family, which includes proteins involved in replication-related processes. RPL36P13 is expressed in most eukaryotic cells and is involved in the regulation of DNA replication by the RPC.

RPL36P13 functions as a negative regulator of the RPC. It binds to the active site of the RPC, which is located at the intersection of the replication fork and the microtubules of the mitotic spindle. By binding to the active site, RPL36P13 prevents the RPC from using the active site for replication. This inhibition leads to the accumulation of replication-related alterations, including the formation of DNA double-strand breaks and the failure of DNA replication.

In addition to its role in regulating the RPC, RPL36P13 is also involved in the regulation of DNA replication in the context of transcription factors. Many transcription factors use the RPC for replication of their genomic DNA, which is then transcribed into RNA and translated into proteins. RPL36P13 is known to interact with transcription factors such as TFAP2, which is involved in the regulation of DNA replication and gene expression.

Drug Targeting

The potential drug targets for RPL36P13 are numerous and varied. One of the most promising targets is the inhibition of RPL36P13, which has been shown to have therapeutic effects in various diseases, including cancer.

One approach to inhibiting RPL36P13 is to use small molecules that can bind to the protein. Many small molecules have been shown to interact with RPL36P13 and have been identified as potential drug targets. One such small molecule is 2-fluoro-4-methoxybenzaldehyde (FMBA), which has been shown to inhibit the activity of RPL36P13. FMBA works by binding to the active site of RPL36P13 and preventing it from functioning as a negative regulator of the RPC.

Another potential drug target for RPL36P13 is the use of CRISPR/Cas9 technology to knockdown the expression of RPL36P13. This approach has been shown to be effective in the regulation of gene expression in various organisms, including humans. By using CRISPR/Cas9 to knockdown the expression of RPL36P13, researchers can study its function and potential as a drug target.

Conclusion

RPL36P13 is a key regulator of the Replication Protein complex and is involved in the regulation of DNA replication in eukaryotic cells. The regulation of the RPC by RPL36P13 is of great interest and potential as a drug target or biomarker. The inhibition of RPL36P13 has been shown to have therapeutic effects in various diseases, including cancer, and the use of small molecules and CRISPR/Cas9 technology is a promising approach to studying its function. Further research is needed to fully understand the role of RPL36P13

Protein Name: Ribosomal Protein L36 Pseudogene 13

The "RPL36P13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL36P13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets